Summary of Mindray Bio-Medical Earnings Call Company Overview - **Company**: Mindray Bio-Medical (300760.SZ) - **Industry**: China Healthcare Key Takeaways Strategic Focus - Mindray is deepening its strategy in "Equipment + Digitalization + Recurrence" to drive sustainability [1] Growth Projections - Overseas sales are expected to maintain a compound annual growth rate (CAGR) of over 10%, with emerging markets (EM) projected at over 15% in the near term [2] - EM accounts for 70% of overseas revenue, with Mindray holding a 13.2% share in equipment and 5.4% in in-vitro diagnostics (IVD) in EM, indicating significant expansion potential [2] IVD Market Insights - IVD is identified as a key mid-term growth and margin driver, despite a 20% year-over-year decline in industry ex-factory average selling prices (ASP) in the first half of 2025 [3] - Mindray's hospital-level reagent output remained flat year-over-year, with sales impacted by base issues [3] Business Initiatives - The new business initiative, MISIA, is projected to grow by 30% in 2025, with overseas sales constituting approximately 40% of total sales [4] - Mindray holds about a 10% market share in the Rmb20 billion MISIA market in China, with ultrasonic scalpels and staplers identified as key near-term growth drivers [4] Financial Performance - Operating cash flow fell by 54% to Rmb3.9 billion in the first half of 2025, attributed to an 11.6% increase in fixed staff costs and front-loaded material procurement to mitigate tariff impacts [9] - The equipment upgrade program accounts for only about 5% of Mindray's sales in China, suggesting limited impact on overall business performance [9] Margin Expectations - Gross profit margin (GPM) and net margin (NM) are expected to decline in 2025 due to regulatory pressures, but stable or improving margins are anticipated from 2026 onwards due to a shift in product mix and cost-cutting measures [9] Market Positioning - In China, Mindray aims to expand its market share in both equipment (34.2%) and IVD (12.8%), with a target for CLIA, biochemistry, and coagulation segments to increase from approximately 10% to 20% over the next three years [9] Financial Metrics - **Market Capitalization**: Rmb300.653 billion - **Price Target**: Rmb260.00, with a current price of Rmb247.31 [6] - **Earnings Per Share (EPS)**: Expected to be Rmb9.03 in 2025, with projections of Rmb10.54 in 2024 [6] Risks and Opportunities Upside Risks - Potential for stronger growth from equipment trade-in policies and faster-than-expected sales ramp-up of key products [12] Downside Risks - Prolonged negative impacts on sales and earnings from policy headwinds and trade tensions [12] Conclusion Mindray Bio-Medical is positioned for growth in both domestic and international markets, with a focus on expanding its product offerings and improving margins despite current challenges in the IVD sector. The company's strategic initiatives and market expansion plans present significant investment opportunities.

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its long-term development despite short-term performance pressures [4][6]. Core Views - The company experienced a significant decline in revenue and net profit in the first half of 2025, with revenue of 16.743 billion yuan, down 18.45% year-on-year, and net profit of 5.069 billion yuan, down 32.96% year-on-year [1]. - The decline in revenue is attributed to extended cycles from public bidding to revenue recognition, reflecting orders from a period of reduced bidding last year [2]. - A recovery in medical equipment bidding activities is expected to improve domestic market revenue in the third quarter of 2025, potentially marking a turning point for the company [2]. - The company continues to invest in research and development, with R&D expenses of 840 million yuan in Q2 2025, representing 9.9% of revenue, and has achieved breakthroughs in various fields [3]. - The company has a strong domestic market presence, covering nearly 110,000 medical institutions and over 99% of top-tier hospitals in China, while also seeing robust growth in international markets [3]. Summary by Sections Financial Performance - In Q2 2025, the company reported revenue of 8.506 billion yuan, a decrease of 23.77% year-on-year, and a net profit of 2.440 billion yuan, down 44.55% year-on-year [1]. - The company's revenue from in vitro diagnostics, life information and support, and medical imaging all saw declines in the first half of 2025 [2]. Research and Development - The company increased its R&D spending to 840 million yuan in Q2 2025, a year-on-year increase of 1.47% [3]. - New products in various fields have been registered, including a new generation of monitoring devices and advanced imaging technology [3]. Market Position and Growth - The company holds a leading market share in several product categories domestically and has expanded its international presence, with significant growth in international in vitro diagnostics and chemiluminescence businesses [3]. - The company’s products are exported to over 190 countries and regions, enhancing its global market penetration [3]. Profit Forecast and Valuation - The profit forecasts for 2025-2027 have been adjusted downward due to industry procurement policies, with expected net profits of 11.309 billion yuan, 13.045 billion yuan, and 14.971 billion yuan respectively [4]. - The current price corresponds to a PE ratio of 26 for 2025, 23 for 2026, and 20 for 2027, reflecting a favorable valuation outlook [4].

Market Performance - The three major indices experienced cumulative gains this week, with the Shanghai Composite Index rising by 0.84%, the Shenzhen Component Index increasing by 4.36%, and the ChiNext Index up by 7.74% [1] - Over 1,700 stocks saw price increases, particularly in the chip, semiconductor, and rare earth permanent magnet sectors [1] Index Details - Shanghai Composite Index: +0.37%, closing at 3,828 points with a trading volume of 1,221.7 billion [3] - Shenzhen Component Index: +0.99%, closing at 12,696 points with a trading volume of 1,576.6 billion [3] - ChiNext Index: +2.23%, closing at 2,890 points with a trading volume of 763.8 billion [3] Notable Stocks - The stock "Kaipu Cloud" surged by 133.74%, leading the gains, while 33 stocks increased by over 30% this week [4][5] - The communication sector had the highest number of stocks with over 30% gains, totaling 6 stocks, followed by the computer sector with 5 stocks [4] Trading Activity - 80 stocks had a turnover rate exceeding 100%, with "Chuanrun Shares" leading at 229.85% [6][7] - The computer, basic chemicals, machinery, and communication sectors had a significant presence among stocks with high turnover rates [6] Fund Flows - No industry saw net inflows from major funds this week, with 11 industries experiencing net outflows exceeding 10 billion [8] - "Gaoer Shares" received the highest net inflow at 1.921 billion, while "Langchao Information" faced the largest net outflow at 3.241 billion [8] Margin Trading - "Shenghong Technology" topped the list for net margin purchases with 4.528 billion, followed by "Hanwuji-U" and "Zhongxin International" with 3.031 billion and 2.868 billion respectively [11][12] Institutional Research - "Mairui Medical" attracted the most attention from institutions, with 397 institutions participating in its research [13][14] - The sectors of focus for institutional research included pharmaceuticals, electronic components, chemicals, and photovoltaics [13] New Institutional Interests - 131 stocks received initial attention from institutions this week, with "Yangnong Chemical" receiving a "Buy" rating and a target price of 93.52 yuan [16][17] - Other stocks like "Tai Ling Micro" and "Dazhu CNC" also garnered initial interest from multiple institutions [16]

Group 1: Economic Transition - The Chinese economy is shifting from a resource-driven growth model to an innovation-driven one, reflecting a structural change in the economy [1] - The integration of new and traditional economies is forming a more robust growth structure [1] Group 2: AI Industry Performance - The AI sector has become a strong market driver, with significant performance growth rooted in actual earnings rather than mere expectations [2] - The computer, electronics, and communication industries reported substantial net profit increases, with respective growth rates of 40.54%, 27.57%, and 7.81% [2] - AI chip leader Cambricon Technologies saw a revenue surge of 4347.82% year-on-year, reaching 2.881 billion yuan, and turned a profit of 1.038 billion yuan after a loss in the previous year [2] Group 3: Traditional Industry Recovery - The "anti-involution" policy has revitalized traditional industries, leading to profit recovery across various sectors [4] - The steel and agriculture sectors reported net profits of 13.137 billion yuan and 27.411 billion yuan, with year-on-year growth rates of 157.17% and 166.72% respectively [4] - Shandong Steel achieved a revenue of 36.806 billion yuan, a year-on-year increase of 118.60%, and turned a profit of 12.5258 million yuan [4] Group 4: Market Signals and Future Outlook - Companies are providing positive signals for future performance, with medical device company Mindray Medical projecting revenue growth in Q3 2025 [7] - Mindray anticipates overall revenue growth and improved performance in both domestic and international markets [7] - Lixun Precision is expected to report a net profit of 10.89 billion to 11.344 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 20% to 25% [8]

深圳迈瑞生物医疗电子股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-034 深圳迈瑞生物医疗电子股份有限公司（下称"本公司"或"公司"）2025年第二次中期 权益分派方案已获2025年8月27日召开的第八届董事会第十三次会议审议通过，在公司2024 年年度股东大会决议授权范围内，无需再次提交股东会审议。现将权益分派事宜公告如下： 一、股东会及董事会审议通过利润分配方案等情况 年第一次中期利润分配预案及提请股东大会授权董事会制定2025年其他中期分红方案的议 案》，同意授权董事会根据股东大会决议在符合利润分配的条件下制定其他具体的2025年中 期分红方案。公司于2025年8月27日召开第八届董事会第十三次会议，审议通过了《关于2025 年第二次中期利润分配方案的议案》，2025年第二次中期利润分配方案为：以公司2025年6 月30日的总股本1,212,441,394股为基数，向全体股东每10股派发现金股利人民币13.10元（含 税），共计派发现金股利人民币1,588,298,226.1 ...

Quantitative Models and Construction Methods 1. Model Name: ChiNext Composite Index (399102.SZ) - **Model Construction Idea**: The ChiNext Composite Index is designed to comprehensively reflect the overall performance of the ChiNext market. It adopts a market capitalization-weighted methodology and includes all eligible listed companies on the ChiNext board[26][27]. - **Model Construction Process**: 1. **Sample Space**: The index includes all A-shares listed on the ChiNext board that meet the following criteria: - Non-ST or *ST stocks - Stocks with a China Securities Index (CSI) ESG rating above grade C[27][28]. 2. **Selection Method**: All stocks in the sample space are included as index constituents, achieving full coverage of the ChiNext market[27]. 3. **Index Calculation**: - The index uses the Paasche weighted method, with May 31, 2010, as the base date and 1,000 points as the base value. - Adjustments for stock splits, dividends, and other corporate actions are made to ensure index continuity[27]. 4. **Adjustment Rules**: - Newly listed stocks are included on the 11th trading day after listing. - Stocks under risk warning or with ESG ratings downgraded to C or below are removed on the second Friday of the following month. - Stocks entering the delisting process are removed immediately[28]. - **Model Evaluation**: The ChiNext Composite Index achieves broad market coverage while incorporating risk control mechanisms (e.g., ESG exclusions), enhancing its representativeness and long-term investment value[18][28]. --- Model Backtesting Results 1. ChiNext Composite Index - **Total Return**: - 2015 to present: 135.06% - 2025 YTD: 36.08%[41][42] - **Annualized Return**: - 2015 to present: 8.24% - 2025 YTD: 59.98%[41][42] - **Annualized Volatility**: - 2015 to present: 30.66% - 2025 YTD: 28.90%[41][42] - **Maximum Drawdown**: - 2015 to present: 67.38% - 2025 YTD: 21.98%[41][42] - **Sharpe Ratio (IR)**: - 2015 to present: 0.27 - 2025 YTD: 2.08[41][42] --- Quantitative Factors and Construction Methods 1. Factor Name: ESG Exclusion Mechanism - **Factor Construction Idea**: The ESG exclusion mechanism aims to enhance the quality and sustainability of the index by removing stocks with poor ESG performance[18][28]. - **Factor Construction Process**: - Stocks with a CSI ESG rating of C or below are excluded from the index. - If a stock's ESG rating improves to above C, it is re-included in the index on the second Friday of the following month[28]. - **Factor Evaluation**: This mechanism reduces tail risks and aligns the index with long-term investment trends, improving its overall quality and attractiveness to institutional investors[18][28]. --- Factor Backtesting Results 1. ESG Exclusion Mechanism - **Impact on Index Performance**: - The mechanism effectively mitigates risks associated with low-quality stocks, contributing to the index's superior risk-adjusted returns (Sharpe ratio of 2.08 in 2025 YTD)[41][42]. - **Impact on Representativeness**: - Despite exclusions, the index maintains comprehensive market coverage, with 1,340 constituent stocks as of August 2025[26][27].

Core Viewpoint - In the first half of 2025, Mindray Medical reported a significant decline in revenue and net profit, primarily due to domestic market challenges and intensified competition in the medical device sector [1][2][3] Financial Performance - Revenue for the first half of 2025 was approximately 16.743 billion yuan, a year-on-year decrease of 18.45% - Net profit was around 5.069 billion yuan, down 32.96% - Operating cash flow decreased by 53.83% to about 3.922 billion yuan [1] Business Segments - The in-vitro diagnostics (IVD) segment generated revenue of approximately 6.424 billion yuan, a decline of 16.11%, with a gross margin decrease of 4.37% to 59.5% - The medical imaging segment reported revenue of 3.312 billion yuan, down 22.51% - The life information and support segment had revenue of 5.479 billion yuan, a decrease of 31.59% [2][3] Domestic Market Challenges - Domestic business faced a decline of over 30%, attributed to healthcare reform, industry regulation, and oversupply during the pandemic - The company anticipates a market recovery starting in Q3 2025, with improved revenue growth expected [1][2] International Business Growth - International revenue accounted for approximately 50% of total revenue, with a year-on-year growth of 5.39% - The international IVD business experienced double-digit growth, while the international medical imaging segment saw mid-single-digit growth [3][4] Future Outlook - The company believes the most challenging period for domestic operations has passed and is focusing on market share growth, particularly in the IVD sector - Mindray is investing in high-value consumables and international markets, expecting significant growth in these areas [2][4] R&D and Financial Position - R&D expenditure for the first half of 2025 was 1.777 billion yuan, representing 10.61% of revenue - As of June 30, 2025, the company held cash and cash equivalents of approximately 16.967 billion yuan [4]

根据调研日期截止日统计，近10日（8月18日至8月29日），海外机构对230家上市公司进行调研，其 中，天孚通信最受关注，被59家海外机构密集调研。 证券时报·数据宝统计显示，近10日共有572家公司获机构调研，调研机构类型显示，证券公司调研达 557家，占比最多；基金公司调研486家，位列其后；海外机构共对230家上市公司进行走访。 海外机构调研榜单中，天孚通信参与调研的海外机构达到59家，最受关注；其次是迈瑞医疗，参与调研 的海外机构共有56家。 从股价表现看，获海外机构调研股近10日平均上涨7.77%。其中，股价上涨的有天孚通信、剑桥科技 等，表现最好的是天孚通信，累计涨幅为84.05%。股价下跌的有62只，跌幅最大的是三德科技，累计 跌幅为13.59%。 从业绩来看，近日获海外机构关注个股中，有187只公布了中期业绩（含快报），净利润增幅居前的有 索通发展、完美世界。 公布中期业绩预告的个股有5只，业绩预告类型来看，预增3只，预降2只。以业绩预告净利润增幅中值 统计，净利润增幅最高的是纳睿雷达，中期净利润同比增长幅度为860.00%。 近10日海外机构调研股 | 证券代码 | 证券简称 | 海外机构家 ...

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Insights - The company achieved a revenue of 16.743 billion RMB in 1H25, a year-over-year decrease of 18.4%, with a net profit attributable to the parent company of 5.069 billion RMB, down 33.0% year-over-year. The performance is in line with expectations, and the company anticipates a positive revenue growth in 3Q25 [1][5] - The gross margin for 1H25 was 61.7%, a decrease of 2.8 percentage points year-over-year, attributed to short-term external factors in the domestic industry. The company continues to strengthen its sales promotion and R&D investments to enhance competitive barriers [2] - The company has three core business segments with clear long-term growth potential: 1. IVD (In Vitro Diagnostics): 1H25 revenue of 6.424 billion RMB, down 16.1% year-over-year, with international business showing double-digit growth [3] 2. Medical Imaging: 1H25 revenue of 3.312 billion RMB, down 22.5% year-over-year, with international business accounting for 62% of the segment [3] 3. Patient Monitoring & Life Support: 1H25 revenue of 5.479 billion RMB, down 31.6% year-over-year, with international revenue making up 67% [3] Revenue and Market Performance - The company reported overseas revenue of 8.332 billion RMB in 1H25, an increase of 5.4% year-over-year, nearly 50% of total revenue. The company is expanding its high-end customer collaborations and developing markets in developing countries [4] - Domestic revenue for 1H25 was 8.411 billion RMB, down 33.4% year-over-year, primarily due to extended revenue recognition cycles from industry tenders. The company expects significant improvement in domestic business in 3Q25 as tender activities recover [4] Profit Forecast and Valuation - The profit forecast has been adjusted due to short-term disruptions affecting revenue growth and gross margin. The expected net profit attributable to the parent company for 2025-2027 is 10.942 billion RMB, 12.360 billion RMB, and 13.976 billion RMB, respectively, with a target price of 333.91 RMB based on a 37x PE ratio for 2025 [5][11]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 300, indicating a potential upside of 21% from the current price of RMB 247.08 [1][2]. Core Insights - The company's performance in 1H25 was significantly under pressure, with revenue of RMB 16.7 billion, a year-on-year decrease of 18%, and a net profit of RMB 4.9 billion, down 33% year-on-year. However, there is a clear expectation for revenue recovery starting in 3Q25, with projected positive year-on-year growth [1][8]. - The report anticipates that the recovery in domestic equipment bidding projects will gradually convert into revenue, leading to further revenue growth in 4Q25. The low base effect from the previous year is expected to accelerate revenue and net profit growth in 2026 [1][8]. Financial Performance and Forecast - The company's revenue and net profit forecasts for the upcoming years are as follows: - Revenue: RMB 34.93 billion in 2023, RMB 36.73 billion in 2024, RMB 37.08 billion in 2025E, RMB 45.94 billion in 2026E, and RMB 53.25 billion in 2027E, with year-on-year growth rates of 15.0%, 5.1%, 1.0%, 23.9%, and 15.9% respectively [2][10]. - Net profit: RMB 11.58 billion in 2023, RMB 11.67 billion in 2024, RMB 11.39 billion in 2025E, RMB 14.49 billion in 2026E, and RMB 17.40 billion in 2027E, with year-on-year growth rates of 20.6%, 0.7%, -2.4%, 27.2%, and 20.1% respectively [2][10]. - The report highlights that the company's international revenue is expected to continue to grow, with a projected double-digit growth rate for the second half of 2025 [1][8]. Segment Analysis - Domestic revenue saw a significant decline of 33% in 1H25, primarily due to prolonged weak bidding conditions for equipment, while international revenue grew by 5%, now accounting for 50% of total revenue [8]. - The report notes that the IVD segment experienced a 16% decline in revenue, attributed to price reductions from centralized procurement and a decrease in testing volumes due to policy changes. However, international IVD business showed resilience with a 12% growth [8].